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It is thought that chronic liver disease affects a person’s risk of cardiovascular disease (CVD)
development. The aim of this study was to assess the effect of Chronic Hepatitis B (HBV) infection,
Chronic Hepatitis C (HCV) infection, and liver damage on cardiovascular risk and selected vascular
parameters contributing to CVD risk. This case-control study included a group of 114 patients
composed of 34 patients with HBV, 35 patients with HCV, and 45 patients as the control group.
Cardiovascular risk was assessed by analyzing classic risk factors, and the SCORE system. The
following arterial properties were analyzed using applanation tonometry with SphygmoCor Vx
technology: central systolic blood pressure (cSBP), central pulse pressure, augmentation pressure,
augmentation index, and carotid-femoral pulse wave velocity (PWV). Asymmetric dimethyloarginine
(ADMA) blood levels were analyzed using ELISA as a marker of vascular function. In a univariable
analysis we found no significant differences between the hepatitis B, hepatitis C, and control groups in
terms of PWV (respectively: median 7.2 [Q25-Q75 6.4-8.5], 7.3 [6.9-8.7], 7.8 [6.5-8.9]), cSBP (115
[109-126], 118 [107-123], 116 [107-129]), ADMA (0.52 [0.47-0.60], 0.53 [0.45-0.62], 0.58
[0.51-0.63]), SCORE (0 [0-1], 0 [0-2], 0 [0-2]). No significant differences in cardiovascular variables
were observed between cirrhotic and non-cirrhotic patients. A multivariable analysis confirmed the
above findings. (PWV, p=0.29; cSBP, p=0.26; ADMA, p=0.19). We concluded that chronic hepatitis
B or C was not independently associated with an adverse cardiovascular risk profile nor with an
unfavorable pattern of vascular parameters contributing to CVD risk in our study population, even in
the case of liver cirrhosis. The same was true for blood ADMA levels.
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It has been thought that liver damage, apart from the
well-researched consequences such as impairment of
detoxification, metabolism, synthesis, and storage,
also affects the cardiovascular system. The exact
mechanism of this, however, has remained unclear
and many aspects of it are completely unexplored. Vi-
ral hepatitides are often a cause of liver impairment.
Especially important among them are hepatitis B and C,
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as these hepatitides can lead to a chronic inflamma-
tory process, and in turn, in some patients, cirrhosis of
the liver. Both infections are significantly problem-
atic worldwide. Globally, approximately 400 million
people suffer from chronic hepatitis B and 170-200
million, chronic hepatitis C (BADAWI et al. 2018,
KARAKECILI et al. 2018). The majority of studies on
the impact of liver disease on cardiovascular disease
(CVD) development conducted thus far have focused
on liver damage in the course of non-alcoholic, fatty
liver disease (NAFLD) (BHALA et al. 2011; MUSSO
et al. 2011; MORITA et al. 2015; VILLELA-NOGUEIRA
et al. 2016). However, the correlation between NAFLD
and CVD is not easy to interpret, the difficulty being
the abundance of confounding factors usally related
to both NAFLD and CVD. In a large percentage of pa-
tients, NAFLD is prompted by the same factors as
CVD; therefore, it might be unclear whether isolated
liver damage leads to CVD (FRANCQUE et al. 2016).
In this context, liver damage caused by viral hepatitis
might represent a better clinical model to assess the
impact of liver dysfunction on CVD risk, and be less
likely to be affected by confounders. However, the
data available in literature in this regard are limited
and inconclusive (TOMIYAMA et al. 2003; MORITANI
et al. 2005; ADAM et al. 2008; PERTICONE et al. 2015).
The aim of the current study was to assess the rela-
tionship between HBV or HCV infection, and se-
lected vascular parameters associated with CVD risk,
while excluding other extrahepatic factors, which
might influence the results. Additionally, we assessed




The study was conducted in accordance with the
Declaration of Helsinki (as revised in Brazil 2013).
Participants had provided written informed consent to
participate in the study. The study protocol was ap-
proved by ethics committees of the Jagiellonian Uni-
versity (1072.6120.21.2017).
This case-control study included 114 patients re-
cruited at the Department of Infectious Diseases, De-
partment of Gastroenterology and Hepatology,
University Hospital in Krakow, Poland and in the
Unit of Cardiology of San Luca Hospital, Istituto
Auxologico Italiano, Milano, Italy, from June 2014 to
June 2019. All study participants were Caucasian and
were recruited from the outpatient services of the in-
stitutions taking part in the study. The study group in-
cluded 34 patients with chronic hepatitis B,
35 patients with chronic hepatitis C, and 45 patients
as a control group. Patients recruited into the control
group were correspondent in age, sex and BMI.
HBV and HCV infection had been excluded before
participation and the exclusion criteria had been met.
Patients from the HBV and HCV groups were divided
into 2 subgroups: non-cirrhotic and cirrhotic. Patients
from the control group were divided into 2 subgroups:
with no liver disease and those with liver cirrhosis due
to some cause other than infection or an autoimmune
issue. A diagnosis of cirrhosis was established based
on typical laboratory results, imaging tests and/or
histopathology, as well as the clinical picture. Exclu-
sion criteria were as follows: age less than 18 years,
pregnancy, a history of CVD (myocardial infarction,
angina pectoris, heart failure, stroke, transient ischae-
mic attacks, or claudication), uncontrolled hyperten-
sion (defined as a brachial systolic blood pressure
(bSBP) 140 mmHg and a brachial diastolic blood
pressure (bDBP) 90 mmHg under treatment), diabe-
tes mellitus, a history of dyslipidemia, and a use of an-
tiaggregants, anticoagulants, or any other CV drugs
besides antihypertensive agents. Diagnosis of hepati-
tis B was based on the presence of HBV-DNA and for
hepatitis C of HCV-RNA in the patients’ blood.
Anthropometric and laboratory assessments
We measured height, body weight, and waist cir-
cumference. Body mass index (BMI) was calculated
as weight/height2. We assessed complete blood count
with differential leukocyte count and the levels of se-
rum alanine transaminase (ALT), aspartate transami-
nase (AST), alkaline phosphatase (ALP),
gamma-glutamyl transpeptydase (GGTP), cholines-
terase, bilirubin, glucose, albumin, ammonia, lipid
profile, C reactive protein (CRP), prothrombin time
(PT), and activated partial thromboplastin time (APTT).
All tests were performed according to generally ac-
cepted standard procedures. In some cases, the data
was incomplete, therefore the corresponding values
of n were given.
Asymmetric dimethyl arginine (ADMA) analysis
Early-morning blood samples after fasting for at
least 12 hours were drawn and collected into serum
separator tubes, samples were allowed to clot for
30 minutes at room temperature and subsequently
centrifuged for 15 minutes at 1000xg at room tem-
perature. Blood samples were stored at -80oC after
centrifugation. The serum level of ADMA was deter-
mined by the ADMA Fast ELISA Kit (DLD, Ger-
many), according to the manufacturer’s instructions.
All samples (standard, control solution 1&2, 66 pa-
tients and 29 controls) were analyzed in duplicate.
The optical density was measured at 450 nm using
a microplate reader (GloMax Multi+ Detection Sys-
tem, Promega, Madison, WI, US) within 15 minutes.
A four parameters logistic (4-PL) curve-fit was used
for quantitative analysis of the samples (Instinct Soft-
ware, Promega, Madison, WI, US).
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Cardiovascular assessments
We performed office blood pressure measurements
twice on the non-dominant arm after 10 minutes of
rest using a Omron M5-I device (Omron, Kyoto, Ja-
pan) and results were averaged, then bSBP, bDBP,
pulse pressure (PP = SBP - DBP), and mean arterial
pressure (MAP) were determined. MAP was calcu-
lated according to the formula: MAP = DBP + 1/3 PP.
Central systolic blood pressure in the aorta (cSBP),
central pulse pressure (cPP), augmentation pressure
(AP), augmentation index (AIx), and pulse wave ve-
locity (PWV) were measured using applanation tono-
metry with the SphygmoCor Vx system (AtCor
Medical, Sydney, NSW, Australia). SCORE (Sys-
tematic Coronary Risk Evaluation) was used to esti-
mate the risk of cardiovascular disease development
among the studied groups (CONROY et al. 2003).
Statistical analysis
All data are presented as means ± standard deviation
(SD) or medians with lower (Q25) and upper (Q75)
quartiles. A normal distribution of variables was veri-
fied using the Shapiro-Wilk test. Univariable com-
parisons between study groups were performed using
the Mann-Whitney U-test and Kruskal-Wallis ANOVA,
as appropriate. In order to determine the associations
of peripheral and central haemodynamic variables
(bSBP,MAP,cSBP, cPP,AP,AIx,PWV)andofADMA
with the clinical characteristics of the study partici-
pants, multivariable linear models were analyzed. In
each model, one of the above variables was included
as a dependent variable and the following as inde-
pendent variables: hepatitis (HBV, HCV or none),
presence of cirrhosis, age, sex, BMI, smoking, and total
cholesterol. Analyses were performed using STATISTICA
13.1 software (StatSoft, Inc., Tulsa, OK, USA), and
statistical significance was defined as p<0.05.
Results
Patient characteristics
The study group included 34 patients with chronic
hepatitis B (mean age 43±12 years, 15 women and
19 men), 35 patients with chronic hepatitis C (mean
age 47±13 years, 11 women and 24 men), and 45 pa-
tients as a control group (mean age 46±12, 20 women
and 25 men).
Among the 34 participants with chronic hepatitis B,
two patients were cirrhotic (liver fibrosis F4), and 32
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Table 1









Age (years) 34 41.5 (32-51) 35 47 (40-53) 45 44 (38-54) 0.23 0.002
BMI (kg/m2) 34 25.6 (21.9-28.7) 35 25.8 (24.6-28.0) 45 24.7 (22.9-26.7) 0.49 0.19
waist cir. (cm) 33 92 (78-100) 35 94 (82-100) 35 88 (77-102) 0.40 0.09
Glycemia (mmol/l) 34 5.1 (4.6-5.3) 33 4.9 (4.7-5.8) 38 5.0 (4.7-5.3) 0.68 0.10
Bilirubine (µmol) 34 9.3 (6.6-15.3) 35 11.2 (8.7-19.4) 36 10.7 (6.6-18.4) 0.53 0.18
Albumin (g/l) 32 45.8 (43.7-47.5) 35 44.5 (40.8-47.0) 35 44.1 (40-46) 0.05 0.001
ALT (U/l) 34 26 (18-38) 35 38 (18-58) 37 24 (17-31) 0.06 0.11
AST (U/l) 34 25 (20-30) 33 30 (24-50) 34 20 (17-30) 0.002 0.01
ALP (U/l) 34 70 (57-86) 33 65 (53-84) 33 66 (52-93) 0.77 0.007
GGTP (U/l) 34 21 (15-41) 33 40 (23-55) 36 33 (18-82) 0.04 <0.001
ChE (Ux103/l) 34 7.67 (6.86-8.53) 33 6.95 (4.94-8.96) 29 6.87 (5.31-8.83) 0.26 0.003
PT (sec) 33 11.6 (11.3-12.1) 35 11.8 (11.2-13.3) 36 11.5 (10.7-12.3) 0.23 0.01
APTT (sec) 33 30.8 (28.5-32.1) 32 31 (28.2-34.8) 35 32 (28.6-34.1) 0.62 <0.001
Platelets (103/µl) 34 231 (194-265) 34 190 (106-225) 40 240 (158-269) 0.02 <0.001
Ammonia (µmol/l) 30 40.5 (31.4-49.8) 30 46.9 (37.6-68.4) 22 49.1 (38.5-67.1) 0.06 0.003
CRP (mg/l) 34 1.3 (0.5-2.1) 32 0.74 (0.30-1.63) 30 1.8 (1.0-6.4) 0.02 0.01
HBV – hepatitis B virus; HCV – hepatitis C virus; Q25, Q75 – lower, upper quartile; BMI – body mass index; ALT – alanine
transaminase; AST – aspartate transaminase; ALP – alkaline phosphatase; GGTP – gamma-glutamyl transpeptydase; ChE –
cholinesterase; PT – prothrombin time; APTT – activated partial thromboplastin time; CRP – C-reactive protein; p# – refers to the
comparison of the HBV, HCV and control group; Kruskal-Wallis test; p## – refers to the comparison of patients with vs. without
cirrhosis; Mann-Whitney U-test (for details see Suppl. 1. in Supplementary materials).
were non-cirrhotic. In 18 of the 32 non-cirrhotic pa-
tients, either core needle biopsy or dynamic elastogra-
phy results were available to assess the extent of liver
fibrosis. Six patients were in the F0 liver fibrosis
stage, three in F1, six in F2, and three in F3. Average
viraemia in the HBV group was 453 068 IU/ml.
Out of the 35 patients with chronic hepatitis C,
16 were cirrhotic (liver fibrosis F4) and 19 non-cirrhotic.
Out of those 19, 18 had a core needle biopsy or dy-
namic elastography performed. One patient placed
in F0, two in F1, twelve in F2, and three in F3. Aver-
age viraemia in the HCV group was 1.3 x 106 IU/ml.
Among the 45 patients from the control group,
34 had no liver disease, and 11 patients were cirrhotic.
Results of the parameters in corresponding groups
Tables 1 and 2 represent the results in the HBV and
HCV groups and the control group. Data in Supple-
mentary Materials (Suppl. 1, and Suppl. 2.) present
data accounting for the cirrhotic and non-cirrhotic
subgroups. There was a clear, statistically significant
difference between the cirrhotic and non-cirrhotic
group in terms of age and in several biochemical vari-
ables emblematic of liver damage (Table 1). Table 2
illustrates the parameters relevant to CVD risk and
ADMA. The only evident, statistically significant
difference was the total cholesterol level between the
HBV and HCV groups, driven by the more numerous
subgroup of cirrhotic patients in the HCV group.
The rest of the parameters did not differ significantly.
A statistically significant difference in SCORE be-
tween the cirrhotic and non-cirrhotic groups disap-
peared when SCORE was adjusted for age (p=0.79).
Chronic hepatitis B and C and their impact on arte-
rial properties, cardiovascular risk, and ADMA, in-
cluding multiple factor analysis
The next step was to compare the parameters rele-
vant to CVD risk and ADMA between the studied
groups, including multivariable analysis, as to avoid
the influence of confounders (including negative
ones) on the results yielded by univariable analysis
(Table 3). Neither HBV, nor HCV infection, nor cir-
rhosis worsened the parameters in question. PWV
was even lower in cirrhotic patients than the non-
cirrhotic ones. The directions of the relations derived
from the regression coefficients for the statistically
significant parameters aligned as expected.
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bSBP (mmHg) 32 128 (120-138) 30 130 (122-137) 40 122 (115-136) 0.33 0.99
bDBP (mmHg) 32 81 (75-86) 30 81 (75-89) 40 80 (72-88) 0.76 0.53
MAP (mmHg) 32 97 (88-103) 30 95 (88-105) 40 92 (84-101) 0.16 0.62
HR (/min) 31 70 (64-74) 24 66 (58-88) 39 76 (65-83) 0.11 0.36
cSBP (mmHg) 31 115 (109-126) 30 118 (107-123) 40 116 (107-129) 0.90 0.99
cPP (mmHg) 31 32 (30-37) 30 36 (30-41) 40 32 (29-37) 0.78 0.09
AP (mmHg) 31 14 (8-17) 30 14 (10-16) 40 12 (8-17) 0.44 0.19
Aix (%) 31 40.5 (25.0-51.7) 30 39.4 (27.5-53.3) 40 37.3 (20.2-51.4) 0.79 0.10
PWV (m/s) 31 7.2 (6.4-8.5) 30 7.3 (6.9-8.7) 40 7.8 (6.5-8.9) 0.57 0.28
SCORE (%) 32 0 (0-1) 30 0 (0-2) 33 0 (0-2) 0.99 0.02
TChol (mmol/l) 34 4.4 (3.9-5.7) 34 4.1 (3.2-4.7) 38 4.6 (3.9-5.0) 0.04 0.19
LDL (mmol/l) 34 2.5 (1.8-3.5) 32 2.1 (1.5-2.7) 37 2.5 (1.8-2.9) 0.21 0.18
HDL (mmol/l) 34 1.6 (1.2-1.9) 32 1.4 (1-1.7) 38 1.3 (1.1-1.7) 0.16 0.87
TG (mmol/l) 34 1.1 (0.7-1.3) 32 0.9 (0.6-1.3) 36 1.1 (0.8-1.4) 0.20 0.45
ADMA (µmol/l) 33 0.52 (0.47-0.60) 30 0.53 (0.45-0.62) 29 0.58 (0.51-0.63) 0.20 0.45
HBV – hepatitis B virus; HCV – hepatitis C virus; Q25, Q75 – lower, upper quartile; bSBP – brachial systolic blood pressure; bDBP –
brachial diastolic blood pressure; MAP – mean arterial pressure; HR – heart rate; cSBP – central systolic blood pressure in aorta; cPP –
central pulse pressure; AP – augmentation pressure; Aix – augmentation index; PWV – pulse wave velocity; TChol – total cholesterol;
LDL – low density lipoprotein cholesterol; HDL – high density lipoprotein cholesterol; TG – triglycerydes; ADMA – asymmetric
dimethyl arginine; p# – refers to the comparison of the HBV, HCV and control group; Kruskal-Wallis test; p## – refers to the
comparison of patients with vs. without cirrhosis; Mann-Whitney U-test (for details see Suppl. 2. in Supplementary materials).
Discussion
From a methodological viewpoint, the model of
liver damage in the course of hepatitis B and hepatitis
C is much better than in the course of NAFLD due to
the fact that it lacks many other, interfering extrahe-
patic factors of CVD and metabolic disorders. Many
patients suffering from chronic hepatitis B and C are
people who, on the one hand exhibit extensive liver
damage, but on the other, do not suffer from other risk
factors of CVD such as diabetes or obesity. However,
the data from hitherto performed studies in a popula-
tion of HBV/HCV-infected patients is ambiguous,
and furthermore, it is worth noting that the qualifica-
tion of patients in the HCV group in some of these
studies was based on the presence of anti-HCV anti-
bodies. Moreover, exclusion criteria did not always
include other cardiovascular diseases, antiaggrega-
tion and anticoagulation therapy, as well as dyslipi-
daemia.
There are several of mechanisms through which,
theoretically, the liver could in fact influence the de-
velopment of CVD; impact on arterial stiffness and
endothelial dysfunction among them (ONI et al.
2013). Arterial stiffness is a product of complex inter-
actions of external factors and structural aspects of the
arterial wall (GKALIAGKOUSI & DOUMA 2009). It is
directly proportional to morbidity and mortality in the
course of CVD in patients with hypertension and
those with diabetes as well as the general population
(LAURENT et al. 2001; WILLUM-HANSEN et al. 2006;
MITCHELL et al. 2010; CARDOSO et al. 2013). The re-
search on arterial stiffness in chronic hepatitis B/C
as contributing to CVD has hitherto been scarce.
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Table 3
Summary of variables associated with peripheral and central haemodynamic parameters and with

































































































































































































p 0.46 0.20 0.35 0.58 0.92 0.76 0.75 0.11
HBV – hepatitis B virus; HCV – hepatitis C virus; BMI – body mass index; TChol – total cholesterol; bSBP – brachial systolic blood
pressure; MAP – mean arterial pressure; cSBP – central systolic blood pressure in aorta; cPP – central pulse pressure; AP –
augmentation pressure; AIx – augmentation index; PWV – pulse wave velocity; ADMA – asymmetric dimethyl arginine.
MORITANI et al. (2005) assessed bSBP, ABI (ankle-
brachial index), and PWV, showing no differences
between HBV, HCV, and control groups. In
TOMIYAMA et al.’s (2003) study, higher values of
PWV in a HCV group were shown in comparison to
a healthy group. No such relation was observed in the
HBV group compared to the healthy group. In a sub-
sequent study, there was no association of arterial
stiffness in HCV patients with insulin resistance
(ADAM et al. 2008). PERTICONE et al. (2015) showed
higher PWV values in the HCV group compared to
controls. WIJARNPREECHA et al. (2016) conducted
a meta-analysis assessing coronary artery disease
(CAD) in those infected with HBV. The authors con-
cluded that HBV infection was not associated with an
increased risk of coronary artery disease, however,
the data obtained for this meta-analysis came mostly
from Asia, therefore its results cannot be transposed
to other populations with a different general cardio-
vascular risk. In the majority of studies included, the
known risk factors of CAD had not been taken into
consideration. BADAWI et al. (2018) analyzed data
from the Canadian Health Measures Survey and the
US-National Health and Nutrition Examination Sur-
vey, and suggested a potential relationship between
HCV infection and clinical and subclinical cardiovas-
cular disease assessed using the Framingham Risk
Factors.
One of the most important results of our study is the
lack of a difference in estimated cardiovascular risk
using the SCORE system between the hepatitis B and
C and control groups. This result supports the conclu-
sion that patients with chronic hepatitis B or C are not
associated with an increased cardiovascular risk.
However, SCORE has a more prognostic, epidemiol-
ogical value than just being useful in quantifying the
real risk of CVD complications. The development of
CVD complications is a continuum and might be bet-
ter assessed by signs of early vascular damage. The
2018 guidelines of the European Society of Cardiol-
ogy (ESC) and European Society of Hypertension
(ESH) recommended the term HMOD (hypertension
mediated organ damage) for those signs (WILIAMS
et al. 2018). HMOD is very important for cardiovas-
cular risk stratification, not only in patients with arte-
rial hypertension. Increased arterial stiffness is one of
the types of HMOD and aortic PWV is considered to
be the gold standard for arterial stiffness evaluation
(VAN BORTEL et al. 2012). The prognostic value of
PWV for cardiovascular complications has been con-
firmed in different groups of patients (LAURENT et al.
2001; WILLUM-HANSEN et al. 2006; CARDOSO et al.
2013; SAFAR et al. 2018). The value of PWV in the ef-
fective prediction of cardiovascular events is compa-
rable to (or stronger than) the Framingham risk score
commonly used worldwide for this purpose
(MITCHELL et al. 2010). Our results demonstrate that
HBV, HCV, and liver damage, even having pro-
gressed to cirrhosis do not affect the indicators of arte-
rial stiffness, closely associated with cardiovascular
prognosis. The only observable correlation was the
association between cirrhosis and PWV. Interest-
ingly, the cirrhotic patients were characterized by
lower PWV than the non-cirrhotic ones. As expected,
age, sex, and BMI did impact CVD risk factors.
No such effect was seen for smoking and blood cho-
lesterol level. The absence of the effect of smoking
could be explained by the fact that a large portion of
the studied group did not smoke altogether. In addi-
tion, the population in question was relatively young,
so the negative effects of smoking might not have
been visible in the tested parameters. The lack of the
effect of cholesterolemia was the result of subject se-
lection. The patients in the HCV group were slightly
older than the other groups, however, that difference
was not statistically significant. The higher median
age stemmed from the fact, that in that group, a larger
percentage of patients suffered from liver cirrhosis,
and those patients were older in all of the study groups
(in the cirrhotic and non-cirrhotic subgroups, the
median age was comparable in every main group).
Patients with liver cirrhosis, despite being more ad-
vanced in age, could have been, to a degree, protected
against atherosclerosis due to lower total cholesterol
and LDL levels. Furthermore, the difference in age
was relatively small considering the rather young age
of the participants, so it was unlikely that such a small
difference would translate to a discernible disparity in
markers of atherosclerosis.
Endothelial dysfunction is an early and, therefore,
crucial element leading to development of CVD.
It occurs even before the formation of atherosclerotic
plaque and fatty streaks (VANHOUTTE 2009). As
a person’s liver deteriorates, the endothelium of he-
patic vessels deteriorates with it. This is a heavily pro-
nounced process in cirrhosis (IWAKIRI et al. 2014).
One of the possible mechanisms of the effect of liver
disease on endothelial dysfunction is the accumula-
tion of ADMA, an endogenic antagonist of NO (nitric
oxide). An increase in ADMA is an established factor
for CVD progression. The liver plays a crucial role in
breaking down ADMA, this process begins to falter
as liver damage progresses and might be the reason
behind an increase in ADMA (DEANFIELD et al.
2007; KASUMOV et al. 2011; FERRIGNO et al. 2015).
ADMA, by blocking the effect of NO, inhibits the
endothelium-dependent vasodilation, as shown in
both human and animal trials (BÖGER et al. 1998;
BÖGER et al. 2000). ADMA is considered to be an im-
portant marker of endothelial dysfunction and corre-
lates to risk factors of CVD (HE et al. 2013). It has
been demonstrated that serum ADMA levels grow in
non-infectious liver disease (NIJVELDT et al. 2003;
LLUCH et al.2004; MOOKERJEE et al. 2007a). Moreo-
ver, those levels correspond to the severity of damage
(MOOKERJEE et al. 2007b). MOOKERJEE et al.
(2007a) have shown that acute liver failure is charac-
terized by an increase in ADMA, which correlates
J. CZEPIEL et al.28
with the intensity of inflammation. During acute liver
failure, ADMA levels grow and, subsequently, fall
significantly in the first few days following a liver
transplant, which points to the liver as key in ADMA
metabolism (SIROEN et al. 2004). So far, there has
been only one study assessing the levels of ADMA in
HBV patients, showing elevated serum ADMA in pa-
tients with chronic hepatitis B (KARAKECILI et al. 2018).
Several studies focusing on ADMA in HCV have
yielded inconsistent results. LLUCH et al.’s (2009)
small group study did not show differences in ADMA
as well as NO in groups with hepatitis C, hepatitis C
after a successful PegIFN+RBV treatment, and healthy
people. However, only patients who retained full liver
function qualified for the study. VIZZUTTI et al. (2007)
have demonstrated HVPG (hepatic venous pressure
gradient) to be directly proportional to ADMA levels and
inversely proportional to NO levels in the serum of pa-
tients with hepatitis C, which could suggest an essential
role of ADMA in portal hypertension in the course of this
disease.Ourstudyhasshownneitheradifference inADMA
stemming from HBV/HCV infection itself nor any ef-
fect of progressive liver damage on ADMA level.
The limitationsofour studywereas follows: a relatively
low number of patients with cirrhosis and chronic hepa-
titis B met our strict inclusion/exclusion criteria. An-
other limitation, perhaps inherent to this type of study,
was that even when we matched patients from the
HBV, HCV, and control groups according to age and
sex, the patients with cirrhosis were older than those
without. Apart from the functional parameters, an-
other important part of atherosclerosis assessment are
the morphological parameters (e.g. the presence of
atheromatous plaque in the carotid arteries or intima-
media complex thickness), which, due to organiza-
tional limitations, have not been included in this
study. However, it does seem that because of the rela-
tively low age of the participants, the functional pa-
rameters have more quantifiable value in this
population (incidence of clinically detectable lesions
in people aged 40-50 is low). Another possible factor
which could impact the studied parameters would be
the duration of infection, however, considering the
course of hepatitis, rarely are we able to confidently
identify the point of transmission of HBV and HCV.
Conclusions
Chronic hepatitis B or C in our study population was not
independently associated with an adverse cardiovascu-
lar risk profile nor with an unfavorable pattern of vascular
parameters contributing to CVD risk, even in the case
of livercirrhosis.Thesameapplied tobloodADMAlevels.
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